公开(公告)号：US20190284177A1

公开(公告)日：2019-09-19

申请号：US16317655

申请日：2017-07-11

Applicant: LEO PHARMA A/S

Inventor： Alan Stuart JESSIMAN ,  Patrick Stephen JOHNSON ,  Kristoffer MAANSSON ,  Morten Dahl SØRENSEN

IPC: C07D413/12 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention relates to a compound according to general formula (I) wherein X represents N or CH; R1 is —CN, (C1-C6)alkyl, (C3-C7)cycloalkyl, (3-7 membered)heterocycloalkyl, (5-6 membered)heteroaryl, (C3-C7)cycloalkyl(C1-C4)alkyl, (3-7 membered)heterocycloalkyl-(C1-C4)alkyl or (5-6 membered)heteroaryl-(C1-C4)alkyl; R2 is halogen, cyano, (C1-C4)alkyl or (C3-C7)cycloalkyl; R3 is halogen, cyano, (C1-C4)alkyl, (C1-C4)haloalkyl or (C3-C7)cycloalkyl; R4 is (C1-C4)alkyl or (C1-C4)haloalkyl; R5 is (C1-C6)alkyl, (C3-C7)cycloalkyl, (C1-C6)alkyl-(C3-C7)cycloalkyl, (C3-C7)cycloalkyl-(C1-C6)alkyl, (3-7 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl or —ORa. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds and to intermediates for preparation of said compounds.

公开(公告)号：US20200291010A1

公开(公告)日：2020-09-17

申请号：US16874961

申请日：2020-05-15

Applicant: LEO PHARMA A/S

Inventor： Alan Stuart JESSIMAN ,  Patrick Stephen JOHNSON ,  Kristoffer MAANSSON ,  Morten Dahl SØRENSEN

IPC: C07D413/12 ,  C07D413/14 ,  C07D417/14 ,  C07D241/04

Abstract: The present invention relates to a compound according to general formula (I) wherein X represents N or CH; R1 is —CN, (C1-C6)alkyl, (C3-C7)cycloalkyl, (3-7 membered)heterocycloalkyl, (5-6 membered)heteroaryl, (C3-C7)cycloalkyl(C1-C4)alkyl, (3-7 membered)heterocycloalkyl-(C1-C4)alkyl or (5-6 membered)heteroaryl-(C1-C4)alkyl; R2 is halogen, cyano, (C1-C4)alkyl or (C3-C7)cycloalkyl; R3 is halogen, cyano, (C1-C4)alkyl, (C1-C4)haloalkyl or (C3-C7)cycloalkyl; R4 is (C1-C4)alkyl or (C1-C4)haloalkyl; R5 is (C1-C6)alkyl, (C3-C7)cycloalkyl, (C1-C6)alkyl-(C3-C7)cycloalkyl, (C3-C7)cycloalkyl-(C1-C6)alkyl, (3-7 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl or —ORa. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds and to intermediates for preparation of said compounds.

公开(公告)号：US20220162191A1

公开(公告)日：2022-05-26

申请号：US17436885

申请日：2020-03-06

Applicant: LEO PHARMA A/S

Inventor： Xifu LIANG ,  Kevin Neil DACK ,  Peter ANDERSEN ,  Morten Dahl SØRENSEN ,  Mark ANDREWS ,  Alan Stuart JESSIMAN

IPC: C07D403/12 ,  C07D401/14 ,  C07D401/12 ,  C07D413/14 ,  C07D471/08 ,  C07D417/14 ,  C07D491/107 ,  C07D491/048 ,  C07D403/14 ,  C07D405/14

Abstract: The present invention relates to a compound according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.